Cargando…

Profile of chimeric RNAs and TMPRSS2-ERG e2e4 isoform in neuroendocrine prostate cancer

PURPOSE: Specific gene fusions and their fusion products (chimeric RNA and protein) have served as ideal diagnostic markers and therapeutic targets for cancer. However, few systematic studies for chimeric RNAs have been conducted in neuroendocrine prostate cancer (NEPC). In this study, we explored t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Qiong, Chen, Junxiu, Singh, Sandeep, Xie, Zhongqiu, Qin, Fujun, Shi, Xinrui, Cornelison, Robert, Li, Hui, Huang, Hai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9463804/ https://www.ncbi.nlm.nih.gov/pubmed/36088396 http://dx.doi.org/10.1186/s13578-022-00893-5

Ejemplares similares

Significance of the TMPRSS2:ERG gene fusion in prostate cancer
por: Wang, Zhu, et al.
Publicado: (2017)

5′ UTR Control of Native ERG and of Tmprss2:ERG Variants Activity in Prostate Cancer
por: Zammarchi, Francesca, et al.
Publicado: (2013)

Quantitative Expression of TMPRSS2 Transcript in Prostate Tumor Cells Reflects TMPRSS2-ERG Fusion Status
por: Mwamukonda, Kuwong, et al.
Publicado: (2009)

Functional antagonism of TMPRSS2-ERG splice variants in prostate cancer
por: Rastogi, Anshu, et al.
Publicado: (2014)

TMPRSS2-ERG fusion promotes prostate cancer metastases in bone
por: Deplus, Rachel, et al.
Publicado: (2016)

Molecular Composition of Genomic TMPRSS2-ERG Rearrangements in Prostate Cancer
por: Krumbholz, Manuela, et al.
Publicado: (2019)

Impact TMPRSS2–ERG Molecular Subtype on Prostate Cancer Recurrence
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2021)

PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis
por: Salagierski, Maciej, et al.
Publicado: (2010)

TMPRSS2-ERG activates NO-cGMP signaling in prostate cancer cells
por: Zhou, Feng, et al.
Publicado: (2019)

Dual TMPRSS2:ERG Fusion in a Patient with Lung and Prostate Cancers
por: Giunchi, Francesca, et al.
Publicado: (2020)

Mapping Isoform Abundance and Interactome of the Endogenous TMPRSS2-ERG Fusion Protein by Orthogonal Immunoprecipitation–Mass Spectrometry Assays
por: Fu, Zhiqiang, et al.
Publicado: (2021)

TMPRSS2-ERG Expression Predicts Prostate Cancer Survival and Associates with Stromal Biomarkers
por: Hägglöf, Christina, et al.
Publicado: (2014)

Presence of TMPRSS2-ERG is associated with alterations of the metabolic profile in human prostate cancer
por: Hansen, Ailin Falkmo, et al.
Publicado: (2016)

Association of germline genetic variants with TMPRSS2-ERG fusion status in prostate cancer
por: Kohaar, Indu, et al.
Publicado: (2020)

Covid-19 pathogenesis in prostatic cancer and TMPRSS2-ERG regulatory genetic pathway
por: Afshari, Afsoon, et al.
Publicado: (2021)

A TMPRSS2‐ERG gene signature predicts prognosis of patients with prostate adenocarcinoma
por: Zhou, Emily, et al.
Publicado: (2020)

TMPRSS2-ERG promotes the initiation of prostate cancer by suppressing oncogene-induced senescence
por: Fang, Lei, et al.
Publicado: (2022)

Nifuroxazide Activates the Parthanatos to Overcome TMPRSS2:ERG Fusion-Positive Prostate Cancer
por: Li, Chengxun, et al.
Publicado: (2023)

PCA3 and TMPRSS2: ERG Urine Level as Diagnostic Biomarker of Prostate Cancer
por: Warli, Syah Mirsya, et al.
Publicado: (2023)

Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer
por: Urbinati, Giorgia, et al.
Publicado: (2015)

TMPRSS2:ERG gene aberrations may provide insight into pT stage in prostate cancer
por: Krstanoski, Zoran, et al.
Publicado: (2016)

Transcriptome Profiling of Prostate Cancer, Considering Risk Groups and the TMPRSS2-ERG Molecular Subtype
por: Kobelyatskaya, Anastasiya A., et al.
Publicado: (2023)

BRD4 Promotes DNA Repair and Mediates the Formation of TMPRSS2-ERG Gene Rearrangements in Prostate Cancer
por: Li, Xiangyi, et al.
Publicado: (2018)

Role of TMPRSS2-ERG Gene Fusion in Negative Regulation of PSMA Expression
por: Yin, Lihong, et al.
Publicado: (2011)

Prevalence of TMPRSS2-ERG and SLC45A3-ERG gene fusions in a large prostatectomy cohort
por: Esgueva, Raquel, et al.
Publicado: (2010)

Two paths for stabilization of ERG in prostate carcinogenesis: TMPRSS2-ERG fusions and speckle-type pox virus and zinc finger protein mutations
por: Pascal, Laura E, et al.
Publicado: (2016)

Status of TMPRSS2–ERG fusion in prostate cancer patients from India: correlation with clinico-pathological details and TMPRSS2 Met160Val polymorphism
por: Bhanushali, Aparna, et al.
Publicado: (2018)

TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling
por: Brase, Jan C, et al.
Publicado: (2011)

Association between TMPRSS2:ERG fusion gene and the prostate cancer: systematic review and meta-analysis
por: García-Perdomo, Herney Andrés, et al.
Publicado: (2018)

TMPRSS2‐ERG fusions linked to prostate cancer racial health disparities: A focus on Africa
por: Blackburn, James, et al.
Publicado: (2019)

Nuclear receptor ERRα and transcription factor ERG form a reciprocal loop in the regulation of TMPRSS2:ERG fusion gene in prostate cancer
por: Xu, Zhenyu, et al.
Publicado: (2018)

EZH2-induced lysine K362 methylation enhances TMPRSS2-ERG oncogenic activity in prostate cancer
por: Zoma, Marita, et al.
Publicado: (2021)

Expression of the TMPRSS2:ERG fusion gene predicts cancer recurrence after surgery for localised prostate cancer
por: Nam, R K, et al.
Publicado: (2007)

Prostate cancer genes associated with TMPRSS2–ERG gene fusion and prognostic of biochemical recurrence in multiple cohorts
por: Barwick, B G, et al.
Publicado: (2010)

Loss of the NKX3.1 tumorsuppressor promotes the TMPRSS2-ERG fusion gene expression in prostate cancer
por: Thangapazham, Rajesh, et al.
Publicado: (2014)

SFRP1 increases TMPRSS2-ERG expression promoting neoplastic features in prostate cancer in vitro and in vivo
por: Cruz-Hernández, Carlos D., et al.
Publicado: (2020)

Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status
por: Dudka, Ilona, et al.
Publicado: (2020)

Comprehensive analysis of oncogenic signatures and consequent repurposed drugs in TMPRSS2:ERG fusion‐positive prostate cancer
por: Yun, Jae Won, et al.
Publicado: (2021)

Prospective evaluation of the role of imaging techniques and TMPRSS2:ERG mutation for the diagnosis of clinically significant prostate cancer
por: Lazzeri, Massimo, et al.
Publicado: (2022)

TMPRSS2-ERG fusions confer efficacy of enzalutamide in an in vivo bone tumor growth model
por: Semaan, Louie, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ilufu4or1m1bnficdni6ovu0uj